Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Revolutionary technology will further boost OneSource’s scientific services offerings
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Shivani Satish Wagh takes on the role of Joint Managing Director
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Nelarabine is a nucleoside metabolic inhibitor indicated for the treatment of patients with T-cell acute lymphoblastic leukemia
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
Subscribe To Our Newsletter & Stay Updated
